ECTRIMS 2024 – BTKi and Diagnostic Criteria (Video)
There were two important highlights at the ECTRIMS Congress 2024 in Copenhagen: The Bruton tyrosine kinase inhibitor (BTKi) Tolebrutinib was able to show in Phase 3 that it significantly slows the progression of disability in
Continue reading